Triple-Drug Therapy Achieves Complete Pancreatic Tumor Regression in Mice With No Resistance Development

A research team at Spain's National Cancer Research Centre just published something I didn't expect to see for years. Complete elimination of pancreatic tumors in mice. No recurrence for over 200 days after they stopped treatment. Published in PNAS last month.

Here's the scientific breakdown and additional research details.

Pancreatic cancer kills 95% of patients. Five-year survival is under 10%. Current targeted therapies buy a few months before tumors develop resistance and keep growing. That's been the wall we've hit for decades.

This approach is different. The team used three drugs simultaneously: RMC-6236 (hits KRAS pathway), Afatinib (already FDA-approved for lung cancer), and SD36 (blocks STAT3). By targeting three independent pathways at once, they shut down the main escape routes tumors use to survive. 16 out of 18 mice had complete regression with no signs of resistance.

If this translates to humans over the next 5-10 years, it changes the game for one of the deadliest cancers we face. And the implications go beyond pancreatic cancer. This multi-pathway strategy could work for other KRAS-driven tumors like lung and colon cancers. The research shows that hitting parallel survival pathways simultaneously prevents the adaptive resistance that limits almost every cancer drug we have.

The study was led by Mariano Barbacid, who discovered the first human oncogene back in 1982. This represents a real shift from trying to hit one target to thinking about cancer as a system with multiple vulnerabilities that need to be attacked together.

The next phase is safety and efficacy validation before human trials can start. CRIS Cancer Foundation, the nonprofit funding this work, is raising €3.5 million for that step. More details here if you're interested: criscancer.org/barbacid

This is the kind of research that takes years to reach patients, but it's also the kind that actually changes outcomes when it does.